Cite
HARVARD Citation
Koch, A. et al. (2017). Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol. NPJ primary care respiratory medicine. pp. 1-6. [Online].